| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| primidone | Tablet, uncoated | 250 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| gentamicin | Injection, solution | 80 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Emergency Supply Only | Manufacturing | 1/11/2024 |
| Pancreatic extract | Capsule, enteric | 150 mg | Resolved | Available | Unexpected increase in consumer demand | 1/11/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 1/11/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 134 mg | Resolved | Available | Manufacturing | 1/11/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| levetiracetam | Tablet, film coated | 500 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 277.5 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Resolved | Available | Manufacturing | 1/11/2024 |
| tranexamic acid | Injection, solution | 1000 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 1/11/2024 |
| acarbose | Tablet | 100 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| acarbose | Tablet | 50 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| acarbose | Tablet | 50 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| cisatracurium besilate | Injection, solution | 14.07 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 1/11/2024 |
| Follitropin alfa | Injection, solution | 75 IU | Current | Unavailable | Manufacturing | 1/11/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 8 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| anastrozole | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 1/11/2024 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Commercial Changes / Commercial viability | 1/11/2024 |
| lacosamide | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 1/11/2024 |
| pregabalin | Capsule, hard | 150 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| pregabalin | Capsule, hard | 25 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| pregabalin | Capsule, hard | 75 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Resolved | Available | Manufacturing | 1/11/2024 |
| norethisterone acetate~estradiol~estradiol | Drug delivery system, transdermal | 4.8 mg~.512 mg~.78 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| estradiol | Drug delivery system, transdermal | .585 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| mycophenolate sodium | Tablet, enteric coated | 384.7 mg | Anticipated | Available | Manufacturing | 1/11/2024 |
| phentermine hydrochloride | Tablet, modified release | 49.7 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| carmustine | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 1/11/2024 |
| cefaclor monohydrate | Oral Liquid, powder for | 52.45 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 1/11/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 1/11/2024 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Current | Unavailable | Manufacturing | 1/11/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 1/11/2024 |
| oxycodone hydrochloride | Oral Liquid, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 1/11/2024 |
| pravastatin sodium | Tablet, uncoated | 40 mg | Current | Unavailable | Manufacturing | 1/11/2024 |
| terbinafine hydrochloride | Tablet, uncoated | 281.3 mg | Anticipated | Available | Manufacturing | 31/10/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 31/10/2024 |
| gabapentin | Tablet, film coated | 600 mg | Anticipated | Available | Manufacturing | 31/10/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Anticipated | Available | Manufacturing | 31/10/2024 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 31/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Limited Availability | Manufacturing | 31/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Unavailable | Manufacturing | 31/10/2024 |
| rizatriptan benzoate | Wafer | 14.53 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 31/10/2024 |
| meloxicam | Capsule, hard | 15 mg | Current | Unavailable | Manufacturing | 31/10/2024 |
| azacitidine | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 31/10/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 31/10/2024 |
| bortezomib | Injection, solution | 3.5 mg | Resolved | Available | Manufacturing | 31/10/2024 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 56.685 mg~1000 mg | Current | Unavailable | Manufacturing | 31/10/2024 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 31/10/2024 |
| clindamycin phosphate | Cream | 22.8 mg/g | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 31/10/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 31/10/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Current | Limited Availability | Manufacturing | 31/10/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Manufacturing | 31/10/2024 |
| morphine sulfate pentahydrate | Tablet, modified release | 60 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| potassium clavulanate~amoxicillin trihydrate | Suspension, powder for | 7.45 mg/mL~28.7 mg/mL | Current | Unavailable | Manufacturing | 30/10/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| cefepime hydrochloride monohydrate | Injection, powder for | 2378.5 mg | Discontinued | Unavailable | Manufacturing | 30/10/2024 |
| cefepime hydrochloride monohydrate | Injection, powder for | 1189.2 mg | Discontinued | Unavailable | Manufacturing | 30/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| tadalafil | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 30/10/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 30/10/2024 |
| dasatinib | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| dasatinib | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| dasatinib | Tablet, film coated | 70 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/10/2024 |
| atomoxetine hydrochloride | Capsule, hard | 45.5 mg | Resolved | Available | Manufacturing | 30/10/2024 |
| gefitinib | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| tamsulosin hydrochloride~dutasteride | Capsule, modified release | 400 microgram~500 microgram | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 30/10/2024 |
| olanzapine | Tablet, uncoated | 2.5 mg | Anticipated | Available | Manufacturing | 30/10/2024 |
| dasatinib propylene glycol | Tablet, film coated | 58 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| dasatinib propylene glycol | Tablet, film coated | 23.2 mg | Discontinued | Unavailable | Manufacturing | 30/10/2024 |
| carbachol | Injection, solution | 100 microgram/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 30/10/2024 |
| octreotide | Injection, solution | 50 microgram/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/10/2024 |
| clarithromycin | Oral Liquid, powder for | 50 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 30/10/2024 |
| Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) | Injection, powder for | 200000000 CFU | Current | Limited Availability | Unexpected increase in consumer demand | 30/10/2024 |
| clindamycin hydrochloride | Solution | 10 mg/mL | Resolved | Available | Manufacturing | 30/10/2024 |
| prazosin hydrochloride | Tablet, uncoated | 1.1 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| prazosin hydrochloride | Tablet, uncoated | 2.2 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| prazosin hydrochloride | Tablet, uncoated | 5.5 mg | Current | Unavailable | Manufacturing | 30/10/2024 |
| morphine sulfate pentahydrate | Tablet, modified release | 10 mg | Current | Unavailable | Manufacturing | 29/10/2024 |
| morphine sulfate pentahydrate | Tablet, modified release | 30 mg | Current | Unavailable | Manufacturing | 29/10/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 29/10/2024 |
| metoprolol succinate | Tablet, modified release | 95 mg | Current | Unavailable | Manufacturing | 29/10/2024 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Anticipated | Available | Manufacturing | 29/10/2024 |
| Digoxinspecific antibody fragment F(ab) (Ovine) | Injection, powder for | 40 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| pemetrexed disodium | Injection, powder for | 1102.9 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Resolved | Available | Manufacturing | 29/10/2024 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Limited Availability | Manufacturing | 29/10/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/10/2024 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Resolved | Available | Unexpected increase in consumer demand | 29/10/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~6.935 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| prasugrel | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 29/10/2024 |
| indometacin | Capsule, hard | 25 mg | Resolved | Available | Manufacturing | 29/10/2024 |
| melatonin | Capsule, hard | 5 mg | Anticipated | Available | Unexpected increase in consumer demand | 29/10/2024 |
| melatonin | Oral Liquid, solution | 1 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 29/10/2024 |
| iopromide | Injection, solution | 498.72 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 29/10/2024 |
| diclofenac sodium | Suppository, moulded | 50 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 29/10/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Resolved | Available | Manufacturing | 28/10/2024 |
| morphine sulfate pentahydrate | Tablet, modified release | 100 mg | Current | Unavailable | Manufacturing | 28/10/2024 |
| sodium polystyrene sulfonate | Powder | 999.3 mg/g | Anticipated | Available | Manufacturing | 28/10/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 28/10/2024 |
| Hepatitis a virus antigen | Injection, suspension | 320 AgU/mL | Resolved | Available | Manufacturing | 28/10/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Anticipated | Available | Manufacturing | 28/10/2024 |
| midazolam | Injection, solution | 1 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 28/10/2024 |
| ziprasidone hydrochloride | Capsule, hard | 65.16 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 28/10/2024 |
| chromium(51Cr) edetate | Injection, solution | 8 MBq/mL | Resolved | Available | Manufacturing | 28/10/2024 |
| esomeprazole | Capsule, enteric | 40 mg | Anticipated | Available | Manufacturing | 28/10/2024 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Resolved | Available | Manufacturing | 28/10/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 28/10/2024 |
| oxycodone hydrochloride | Capsule, hard | 10 mg | Resolved | Available | Commercial Changes / Commercial viability | 28/10/2024 |
| morphine sulfate pentahydrate | Capsule, modified release | 60 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 28/10/2024 |
| pamidronate disodium | Injection, concentrated | 3 mg | Resolved | Available | Manufacturing | 28/10/2024 |
| pamidronate disodium | Injection, concentrated | 6 mg | Resolved | Available | Manufacturing | 28/10/2024 |
2024年11月4日